Innocan Pharma Corporation (OTCMKTS:INNPF) Stock In Focus After Success in a Pre-Clinical Trial

Leading biotech and pharmaceutical firm Innocan Pharma Corporation (OTCMKTS:INNPF) was one of the companies to have come into focus on Monday following a key announcement. The company announced that Billy, a 4 year old neutered male goat, had been successfully treated with liposomal CBD injection as part of a pre-clinical trial.

Trading Data

On Monday, INNPF stock ended flat at $0.1430 with more than 3.60K shares traded, compared to volume of 392 shares. The stock moved within a range of $0.1430 – 0.1430 after opening trading at $0.1430.

Innocan Pharma Reports Success in a Pre-Clinical Trial of a Liposomal-CBD Injection on a Paralyzed Goat

The company noted that the innovative theory had also provided relief to the animal, which had been born with scoliosis and neurological deficits. The conditions had resulted fore limb deformity and paralysis of the hind limb. The reason why it was a major new development for Innocan Pharma was due to the fact that successful pre-clinical trials on large mammals like goats is generally an indication of the bio-feasibility of the product in human beings as well.

Billy had found it possible to move around in a wheelchair but due to the rise in his size and weight, his conditions turned worse and his mobility went down substantially. While he had been provided anti-inflammatory medicines, the pain remained a constant and it was difficult for Billy to move around in his wheelchair.

The liposomal CBD injection is a unique product from Innocan Pharma since it helps in delivery of CBD to specific areas in the body.